Literature DB >> 20876810

Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Gang Chen1, Nino E Giambrone, Douglas F Dluzen, Joshua E Muscat, Arthur Berg, Carla J Gallagher, Philip Lazarus.   

Abstract

Glucuronidation is an important pathway in the metabolism of nicotine, with previous studies suggesting that ∼22% of urinary nicotine metabolites are in the form of glucuronidated compounds. Recent in vitro studies have suggested that the UDP-glucuronosyltransferases (UGT) 2B10 and 2B17 play major roles in nicotine glucuronidation with polymorphisms in both enzymes shown to significantly alter the levels of nicotine-glucuronide, cotinine-glucuronide, and trans-3'-hydroxycotinine (3HC)-glucuronide in human liver microsomes in vitro. In the present study, the relationship between the levels of urinary nicotine metabolites and functional polymorphisms in UGTs 2B10 and 2B17 was analyzed in urine specimens from 104 Caucasian smokers. Based on their percentage of total urinary nicotine metabolites, the levels of nicotine-glucuronide and cotinine-glucuronide were 42% (P < 0.0005) and 48% (P < 0.0001), respectively, lower in the urine from smokers exhibiting the UGT2B10 (*1/*2) genotype and 95% (P < 0.05) and 98% (P < 0.05), respectively, lower in the urine from smokers with the UGT2B10 (*2/*2) genotype compared with the urinary levels in smokers having the wild-type UGT2B10 (*1/*1) genotype. The level of 3HC-glucuronide was 42% (P < 0.001) lower in the urine from smokers exhibiting the homozygous UGT2B17 (*2/*2) deletion genotype compared with the levels in urine from wild-type UGT2B17 subjects. These data suggest that UGTs 2B10 and 2B17 play important roles in the glucuronidation of nicotine, cotinine, and 3HC and suggest that the UGT2B10 codon 67 SNP and the UGT2B17 gene deletion significantly reduce overall glucuronidation rates of nicotine and its major metabolites in smokers.
© 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876810      PMCID: PMC2998997          DOI: 10.1158/0008-5472.CAN-09-4582

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

2.  Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine.

Authors:  W S Caldwell; J M Greene; G D Byrd; K M Chang; M S Uhrig; J D deBethizy; P A Crooks; B S Bhatti; R M Riggs
Journal:  Chem Res Toxicol       Date:  1992 Mar-Apr       Impact factor: 3.739

3.  Direct determination of cotinine-N-glucuronide in urine using thermospray liquid chromatography/mass spectrometry.

Authors:  G D Byrd; M S Uhrig; J D deBethizy; W S Caldwell; P A Crooks; A Ravard; R m Riggs
Journal:  Biol Mass Spectrom       Date:  1994-02

4.  Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4-(3-pyridyl)butanoic acid in human urine: A substantial pathway of nicotine metabolism.

Authors:  S S Hecht; D K Hatsukami; L E Bonilla; J B Hochalter
Journal:  Chem Res Toxicol       Date:  1999-02       Impact factor: 3.739

5.  Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine.

Authors:  N L Benowitz; P Jacob; I Fong; S Gupta
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

6.  Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15.

Authors:  Willie Wilson; Fernando Pardo-Manuel de Villena; Beverly D Lyn-Cook; Pradeep K Chatterjee; Timothy A Bell; David A Detwiler; Rodney C Gilmore; Isis C Valladeras; Camille C Wright; David W Threadgill; Delores J Grant
Journal:  Genomics       Date:  2004-10       Impact factor: 5.736

7.  N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases.

Authors:  Gwendolyn E Kuehl; Sharon E Murphy
Journal:  Drug Metab Dispos       Date:  2003-11       Impact factor: 3.922

8.  Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

9.  Metabolism of nicotine to cotinine studied by a dual stable isotope method.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1994-11       Impact factor: 6.875

10.  A human minor histocompatibility antigen resulting from differential expression due to a gene deletion.

Authors:  Makoto Murata; Edus H Warren; Stanley R Riddell
Journal:  J Exp Med       Date:  2003-05-12       Impact factor: 14.307

View more
  34 in total

1.  Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Authors:  Paula L Vieira-Brock; Eleanor I Miller; Shannon M Nielsen; Annette E Fleckenstein; Diana G Wilkins
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-09-18       Impact factor: 3.205

2.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Authors:  Kathryn Kelly Erickson-Ridout; Junjia Zhu; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

3.  Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Authors:  Douglas F Dluzen; Dongxiao Sun; Anna C Salzberg; Nate Jones; Ryan T Bushey; Gavin P Robertson; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2014-01-07       Impact factor: 4.030

4.  A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.

Authors:  Taraneh Taghavi; Maria Novalen; Caryn Lerman; Tony P George; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-31       Impact factor: 4.254

5.  Differences in nicotine dependence, smoke exposure and consumer characteristics between smokers of machine-injected roll-your-own cigarettes and factory-made cigarettes.

Authors:  Sarah Joseph; Nicolle M Krebs; Junjia Zhu; Yijin Wert; Reema Goel; Samantha M Reilly; Dongxiao Sun; John P Richie; Ivan Nikiforov; Pramil Cheriyath; Joshua E Muscat
Journal:  Drug Alcohol Depend       Date:  2018-04-07       Impact factor: 4.492

6.  Detoxification and elimination of nicotine by nectar-feeding birds.

Authors:  S Lerch-Henning; E E Du Rand; S W Nicolson
Journal:  J Comp Physiol B       Date:  2017-02-01       Impact factor: 2.200

7.  UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.

Authors:  Nathan R Jones; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2014-01-23       Impact factor: 3.922

8.  UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.

Authors:  Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

9.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

10.  Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.

Authors:  Gang Chen; Shaman Luo; Shannon Kozlovich; Philip Lazarus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-09       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.